Infectious Diseases II
1314. https://doi.org/10.1001/jama.2022.17034
Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko
WC. Cefepime therapy for monomicrobial bacteremia
caused by cefepime-susceptible extended-spectrum
beta-lactamase-producing
Enterobacteriaceae:
MIC
matters. Clin Infect Dis. 2013;56(4):488-495. https://doi.
org/10.1093/cid/cis916
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice
guidelines by the Infectious Diseases Society of America
for the treatment of methicillin-resistant Staphylococcus
aureus infections in adults and children: executive sum-
mary. Clin Infect Dis. 2011;52(3):285-292. https://doi.
org/10.1093/cid/cir034
Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-
IMI 1: a multicenter, randomized, double-blind trial
comparing efficacy and safety of imipenem/relebactam
vs colistin plus imipenem in patients with imipenem-
nonsusceptible bacterial infections. Clin Infect Dis.
2020;70(9):1799-1808. https://doi.org/10.1093/cid/ciz530
Nation RL, Garonzik SM, Thamlikitkul V, et al.
Dosing guidance for intravenous colistin in critically-ill
patients. Clin Infect Dis. 2017;64(5):565-571. https://doi.
org/10.1093/cid/ciw839
Prasad P, Sun J, Danner RL, Natanson C. Excess deaths
associated with tigecycline after approval based on non-
inferiority trials. Clin Infect Dis. 2012;54(12):1699-1709.
https://doi.org/10.1093/cid/cis270
Prokocimer P, De Anda C, Fang E, Mehra P, Das
A. Tedizolid phosphate vs linezolid for treat-
ment of acute bacterial skin and skin structure
infections:
the
ESTABLISH-1
randomized
trial.
2013;309(6):559-569.
https://doi.org/10.1001/
jama.2013.241
Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment
outcome
of
bacteremia
due
to
KPC-producing
Klebsiella pneumoniae: superiority of combination
antimicrobial regimens. Antimicrob Agents Chemother.
2012;56(4):2108-2113.
https://doi.org/10.1128/
aac.06268-11
Retamar P, LΓ³pez-Cerero L, Muniain MA, et al;
ESBL-REIPI/GEIH Group. Impact of the MIC of
piperacillin-tazobactam on the outcome of patients
with
bacteremia
due
to
extended-spectrum-Ξ²-
lactamase-producing Escherichia coli. Antimicrob
Agents Chemother. 2013;57(7):3402-3404. https://doi.
org/10.1128/aac.00135-13
RodrΓguez-BaΓ±o J, Navarro MD, Retamar P, et al;
Extended-Spectrum Beta-LactamasesβRed EspaΓ±ola de
InvestigaciΓ³n en PatologΓa Infecciosa/Grupo de Estudio
de InfecciΓ³n Hospitalaria Group. Ξ²-Lactam/Ξ²-lactam
inhibitor combinations for the treatment of bactere-
mia due to extended-spectrum Ξ²-lactamase-producing
Escherichia coli: a post hoc analysis of prospective
cohorts. Clin Infect Dis. 2012;54(2):167-174. https://doi.
org/10.1093/cid/cir790
Rybak MJ. Resistance to antimicrobial agents: an update.
doi.org/10.1592/phco.24.18.203s.52236
Rybak MJ, Le J, Lodise TP, et al. Therapeutic moni-
toring of vancomycin for serious methicillin-resistant
Staphylococcus aureus infections: a revised consensus
guideline and review by the American Society of Health-
System Pharmacists, the Infectious Diseases Society of
America, the Pediatric Infectious Diseases Society, and
Health Syst Pharm. 2020;77(11):835-864. https://doi.
org/10.1093/ajhp/zxaa036
Solomkin J, Evans D, Slepavicius A, et al. Assessing the
efficacy and safety of eravacycline vs ertapenem in com-
plicated intra-abdominal infections in the investigating
gram-negative infections treated with eravacycline
Surg.
2017;152(3):224-232.
https://doi.org/10.1001/
jamasurg.2016.4237
Tamma PD, Girdwood SC, Gopaul R, et al. The use of
cefepime for treating AmpC Ξ²-lactamase-producing
Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781-788.
https://doi.org/10.1093/cid/cit395
Tamma PD, Heil EL, Justo JA, et al. IDSA 2024 guidance
on the treatment of antimicrobial resistant gram-negative
infections. Clin Infect Dis. 2024 Aug 7:ciae403. https://
doi.org/10.1093/cid/ciae403
Tasina E, Haidich AB, Kokkali S, Arvanitidou M.
Efficacy and safety of tigecycline for the treatment of
Dis.
2011;11(11):834-844.
https://doi.org/10.1016/
s1473-3099(11)70177-3
Tumbarello M, Viale P, Viscoli C, et al. Predictors of
mortality in bloodstream infections caused by Klebsiella
pneumoniae carbapenemase-producing K. pneumoniae: